TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›LFVN
LFVN logo

LFVN

Lifevantage Corp

Next earnings Sep 2, 2026 (after close) · consensus $0.13 EPS, $46.9M rev

Last earnings +9.3% on 2026-05-06

Buy
$6.22
▲ +0.32%
$6.22▼ -49.67%
over 1Y
L $3.99H $14.13
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.3%
1W-6.5%
1M-27.8%
3M+47.3%
YTD+4.8%
1Y-49.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
B
Valuation
Undervalued
Filings
Flagged
Buy
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 8 analysts
Buy

Debt-free, cash-generative nutraceutical at 8x earnings after a breakout FY25 — cheap enough to own despite the fragile MLM model.

P/E (price / FY diluted EPS) 8.3 · FY2025 / current price

The read

Quality fundamentals and an attractive price line up (~358% below fair value) — the rarer case where both the business and the entry look good.

LFVN just printed its best year in half a decade: FY2025 revenue of $229M (+14.2%) reversed the 2021–2024 stagnation ($220M→$206M→$213M→$200M), and net income leapt to $9.80M (+233.8%) on operating income of $12.2M (+181.6%). The economics underneath are genuinely attractive — 80.4% gross margin, 28.3% ROE, $11.9M operating cash flow against just $1.37M capex (~$10.5M free cash flow), $20.2M cash and effectively no debt (last reported long-term and current debt both $0; only an undrawn $5.0M line). At $6.20 the stock trades at 8.3x diluted EPS of $0.75, 0.3x sales, and a low-teens FCF yield. For a profitable, self-funding business returning cash via dividends and buybacks, that is a cheap absolute multiple.

The catch is what kind of business it is. LFVN is a direct-selling (MLM) operation whose revenue is only as durable as its independent-consultant base, and the 10-K is unusually candid: it has 'experienced discord among our leading independent consultants,' warns that the departure of a single leader 'can be a major disruption,' and flags ongoing legal proceedings with former consultants plus broad regulatory exposure. The five-year revenue line — flat-to-down for four years before this year's pop — shows exactly how fragile the top line is, and net income has swung from $12.9M (FY21) to ~$2.5–3M (FY22–24) and back to $9.80M. One strong year does not establish a trend, and the deeply negative retained earnings (-$104M) reflect a history of returning more cash than the franchise has durably earned.

Is LFVN a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bull call spread~60d expiry
  • Long call 6 @ ~1.64 est
  • Short call 7 @ ~1.28 est
debit $36max +$64max −$36BE 6.36

BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$220M$206M$213M$200M$229M
Gross profit$182M$168M$170M$159M$184M
Operating income$17.6M$7.58M$4.26M$4.33M$12.2M
Net income$12.9M$3.12M$2.54M$2.94M$9.80M
Diluted EPS$0.90$0.24$0.20$0.23$0.75
Net margin5.9%1.5%1.2%1.5%4.3%

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$58.3M
EV / EBITDA3.8
EV / Sales0.3
EV / FCF5.5
P / FCF7.5
PEG (trailing)0.04
Earnings yield12.5%
FCF yield13.4%

Quality & risk

ROIC (est.)27.8%
Free cash flow$10.5M
Total debt$0.00
Net cash$20.2M
Altman Z-Score3.37 safe
Piotroski F-Score7/9

Capital returns

Buyback yield4.0%
Dividend yield (est.)2.6%
Shareholder yield6.6%
Shares Δ YoY+1.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 8-K Earnings results2026-05-06

    Q3 FY26 quarterly report (period 2026-03-31) filed

  2. 10-Q Quarterly report2026-05-06

    Q3 FY26 quarterly report (period 2026-03-31) filed

  3. 8-K Officer / director change2026-04-16

    Officer/director change (Item 5.02); leadership transition disclosed

  4. S-3 Shelf registration (potential raise)2026-03-10

    Refiled $75M shelf registration; preserves capital access, possible dilution

  5. 8-K Officer / director change2026-02-04

    Q2 FY26 quarterly report filed

  6. 10-Q Quarterly report2026-02-04

    Q2 FY26 quarterly report filed

  7. 8-K Officer / director change2025-12-09

    Officer/director departure or appointment (Item 5.02)

  8. 8-K Shareholder vote2025-11-12

    Annual meeting voting results disclosed (Item 5.07)

  9. 8-K Earnings results2025-11-04

    Q1 FY26 quarterly report filed

Recent filings

all on EDGAR ↗
4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-032026-06-05open ↗144Filing2026-06-03open ↗8-KPeriod ending 2026-05-062026-05-06open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-04-132026-04-16open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗SCHEDULE 13G/AFiling2026-04-02open ↗EFFECTFiling2026-03-20open ↗

Quality score

B
ValueGrowthProfitHealthMom.
ValueA+
GrowthA
ProfitabilityB
Financial healthB+
MomentumF
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✓P/E below 25

Fair value est.

$28.50

Undervalued +358% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.75 × (8.5 + 1.5 × 22.0% growth) × 1.04 quality = 38.0× multiple. An estimate, not a price target.

3.9952-week14.13
Revenue
$229M
+14.2% YoY
Net margin
4.3%
ROE
28.3%
P/E
8.3

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$229M+14.2%
Net income$9.80M+233.8%
Gross profit$184M+15.7%
Operating income$12.2M+181.6%
Diluted EPS$0.75+226.1%
Cash & equivalents$20.2M+19.6%
Total assets$72.0M+19.3%
Total liabilities$37.3M+8.8%
Stockholders' equity$34.6M+33.3%
Gross: 80.4%Op.: 5.3%L/E: 1.08x

Frequently asked

Is Lifevantage Corp (LFVN) a buy?
LFVN currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Debt-free, cash-generative nutraceutical at 8x earnings after a breakout FY25 — cheap enough to own despite the fragile MLM model.
What is LFVN's fair value?
A Modified-Graham model based on LFVN's SEC fundamentals estimates a fair value of about $28.50. It is an estimate from reported earnings, not a price target.
Is LFVN overvalued or undervalued?
Against a Modified-Graham fair-value estimate, LFVN currently appears undervalued relative to its SEC-grounded earnings power.
What is Lifevantage Corp's quality score?
LFVN scores 74.47053807987409/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000849146, latest 10-Q filed 2026-05-06) · EODHD · Proprietary analysis · as of 6/30/2026, 12:29:51 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 30, 2026, 8:29 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 1 open-market buy · 1 sale

2026-06-15
Lewis Darwin
Director
Buy705.00 @ $8.60$6.06K
2026-06-03
BEINDORFF MICHAEL A
Director
Sell10.0K @ $8.55$85.5K
2026-04-01
Neufeld Alissa
General Counsel
Tax1.45K @ $4.20$6.07K
2026-04-01
Fife Steven R
President and CEO
Tax8.18K @ $4.20$34.4K
2026-04-01
Aure Carl
Chief Financial Officer
Tax1.53K @ $4.20$6.41K
2026-04-01
Cunningham Kristen
Chief Sales Officer
Tax1.93K @ $4.20$8.10K
2026-03-16
Lewis Darwin
Director
Buy1.05K @ $5.23$5.52K
2026-03-02
Dayton Judd
Director
Buy10.5K @ $4.53$47.6K
2026-02-27
Dayton Judd
Director
Buy18.1K @ $4.63$83.8K
2026-02-26
Dayton Judd
Director
Buy4.60K @ $4.58$21.1K

Earnings history

beat/miss · move
2026-05-06Miss -24.9% est▲ +0.19%8-K ↗
2026-02-04Miss -2.0% est▼ -15.38%8-K ↗
2025-11-04Miss -4.6% est▼ -9.65%8-K ↗
2025-09-04Miss -5.1% est▼ -7.56%8-K ↗
2025-05-06—▲ +0.68%8-K ↗
2025-02-05—▼ -15.22%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score74 vs 67
Revenue growth14.2% vs 7.5%
Net margin4.3% vs 10.0%
Return on equity28.3% vs 12.0%
P/E8.3 vs 26.2